Pharming Group N.V. (PHAR) Operating Leases (2019 - 2024)

Pharming (PHAR) has disclosed Operating Leases for 4 consecutive years, with $29.5 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Operating Leases fell 1.13% year-over-year to $29.5 million, compared with a TTM value of $29.5 million through Dec 2023, down 1.13%, and an annual FY2023 reading of $29.5 million, down 1.13% over the prior year.
  • Operating Leases was $29.5 million for Q4 2023 at Pharming, down from $29.8 million in the prior quarter.
  • Across five years, Operating Leases topped out at $29.8 million in Q4 2022 and bottomed at $8.2 million in Q4 2020.
  • Average Operating Leases over 4 years is $22.1 million, with a median of $25.2 million recorded in 2021.
  • The sharpest move saw Operating Leases skyrocketed 153.65% in 2021, then fell 1.13% in 2023.
  • Year by year, Operating Leases stood at $8.2 million in 2020, then soared by 153.65% to $20.9 million in 2021, then surged by 42.96% to $29.8 million in 2022, then decreased by 1.13% to $29.5 million in 2023.
  • Business Quant data shows Operating Leases for PHAR at $29.5 million in Q4 2023, $29.8 million in Q4 2022, and $20.9 million in Q4 2021.